oral semaglutide for obesity VisualAbstract:Oral effectively reduces bodyweight in non-diabetic adults with FDA Approves Oral Semaglutide as

Claims-based data from FairHealth found the number of adults prescribed a GLP-1 drug increased from 0.9% in 2019 to 4% in 2024, and the number of adults with overweight, obesity or diabetes prescribed the medications increased from 0.3% in 2019 to 2.05% in 2024

Personalized Dosage & Flexible Treatment Tailored to your unique needs, our injectable semaglutide offers flexible dosing that seamlessly fits into your lifestyle

Analytical Testing Every batch undergoes comprehensive HPLC peptide analysis, LC-MS identity confirmation, purity verification, and laboratory quality control to support reproducible scientific research

The medication remains in Phase 3 clinical trials, with many additional trial readouts expected throughout 2026